SeaStar Medical Q2 Revenue Jumps 82% as Pediatric AKI Device Gains Traction
ICU sits 62% above its 52-week low of $2.07.
Summary
SeaStar Medical reported Q2 2026 net revenue of $0.6M, up 82% year-over-year, driven by three new top-rated children's hospital customers for its QUELIMMUNE pediatric AKI device. Gross margins held at 91%. The company also advanced its NEUTRALIZE-AKI pivotal trial to 223 of 339 enrolled adult patients, with enrollment completion expected around year-end or early 2027. New ICD-10-PCS billing codes take effect October 1, 2026, which should streamline hospital reimbursement. The company remains in a going-concern situation with less than 12 months of cash, so the revenue growth and trial progress are critical to its survival.
At the time of this announcement, ICU was trading at $3.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.4M. The 52-week trading range was $2.07 to $12.50. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.